These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 15749128

  • 1. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques.
    Amara RR, Sharma S, Patel M, Smith JM, Chennareddi L, Herndon JG, Robinson HL.
    Virology; 2005 Mar 30; 334(1):124-33. PubMed ID: 15749128
    [Abstract] [Full Text] [Related]

  • 2. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
    Smith JM, Amara RR, McClure HM, Patel M, Sharma S, Yi H, Chennareddi L, Herndon JG, Butera ST, Heneine W, Ellenberger DL, Parekh B, Earl PL, Wyatt LS, Moss B, Robinson HL.
    AIDS Res Hum Retroviruses; 2004 Jun 30; 20(6):654-65. PubMed ID: 15242543
    [Abstract] [Full Text] [Related]

  • 3. Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.
    Geels MJ, Dubey SA, Anderson K, Baan E, Bakker M, Pollakis G, Paxton WA, Shiver JW, Goudsmit J.
    J Virol; 2005 Sep 30; 79(17):11247-58. PubMed ID: 16103177
    [Abstract] [Full Text] [Related]

  • 4. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ, Patrick A, Moss RB, Rosenthal KL.
    J Virol; 2005 Jan 30; 79(1):393-400. PubMed ID: 15596832
    [Abstract] [Full Text] [Related]

  • 5. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
    Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L, Hudacik L, Whitney S, Keen T, Chou TH, Shen S, Joshi S, Kalyanaraman VS, Nair B, Markham P, Lu S, Pal R.
    Virology; 2006 Mar 01; 346(1):151-68. PubMed ID: 16325880
    [Abstract] [Full Text] [Related]

  • 6. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
    Thakar MR, Bhonge LS, Lakhashe SK, Shankarkumar U, Sane SS, Kulkarni SS, Mahajan BA, Paranjape RS.
    J Infect Dis; 2005 Sep 01; 192(5):749-59. PubMed ID: 16088824
    [Abstract] [Full Text] [Related]

  • 7. Differential immunogenicity of HIV-1 clade C proteins in eliciting CD8+ and CD4+ cell responses.
    Ramduth D, Chetty P, Mngquandaniso NC, Nene N, Harlow JD, Honeyborne I, Ntumba N, Gappoo S, Henry C, Jeena P, Addo MM, Altfeld M, Brander C, Day C, Coovadia H, Kiepiela P, Goulder P, Walker B.
    J Infect Dis; 2005 Nov 01; 192(9):1588-96. PubMed ID: 16206073
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ, Otten GR, Doe B, Liu H, Srivastava R, Greer C, Legg H, Tang T, Polo JM, Donnelly JJ, Ulmer JB, Barnett SW.
    Vaccine; 2006 Apr 05; 24(15):2755-63. PubMed ID: 16460840
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
    Cao H, Kaleebu P, Hom D, Flores J, Agrawal D, Jones N, Serwanga J, Okello M, Walker C, Sheppard H, El-Habib R, Klein M, Mbidde E, Mugyenyi P, Walker B, Ellner J, Mugerwa R, HIV Network for Prevention Trials.
    J Infect Dis; 2003 Mar 15; 187(6):887-95. PubMed ID: 12660934
    [Abstract] [Full Text] [Related]

  • 10. Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, better conservation of CD8 than CD4 T cell responses.
    Smith JM, Amara RR, Wyatt LS, Ellenberger DL, Li B, Herndon JG, Patel M, Sharma S, Chennareddi L, Butera S, McNicholl J, McClure HM, Moss B, Robinson HL.
    AIDS Res Hum Retroviruses; 2005 Feb 15; 21(2):140-4. PubMed ID: 15725752
    [Abstract] [Full Text] [Related]

  • 11. HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response.
    Boyer JD, Chattergoon M, Shah A, Ginsberg R, MacGregor RR, Weiner DB.
    Dev Biol Stand; 1998 Feb 15; 95():147-53. PubMed ID: 9855425
    [Abstract] [Full Text] [Related]

  • 12. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
    Bazhan SI, Belavin PA, Seregin SV, Danilyuk NK, Babkina IN, Karpenko LI, Nekrasova NA, Lebedev LR, Ignatyev GM, Agafonov AP, Poryvaeva VA, Aborneva IV, Ilyichev AA.
    Vaccine; 2004 Apr 16; 22(13-14):1672-82. PubMed ID: 15068850
    [Abstract] [Full Text] [Related]

  • 13. Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens.
    Bolesta E, Gzyl J, Wierzbicki A, Kmieciak D, Kowalczyk A, Kaneko Y, Srinivasan A, Kozbor D.
    Virology; 2005 Feb 20; 332(2):467-79. PubMed ID: 15680412
    [Abstract] [Full Text] [Related]

  • 14. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.
    Xu J, Ren L, Huang X, Qiu C, Liu Y, Liu Y, Shao Y.
    AIDS; 2006 Nov 28; 20(18):2293-303. PubMed ID: 17117015
    [Abstract] [Full Text] [Related]

  • 15. Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques.
    Amara RR, Ibegbu C, Villinger F, Montefiori DC, Sharma S, Nigam P, Xu Y, McClure HM, Robinson HL.
    Virology; 2005 Dec 20; 343(2):246-55. PubMed ID: 16185742
    [Abstract] [Full Text] [Related]

  • 16. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.
    De Groot AS, Bishop EA, Khan B, Lally M, Marcon L, Franco J, Mayer KH, Carpenter CC, Martin W.
    Methods; 2004 Dec 20; 34(4):476-87. PubMed ID: 15542374
    [Abstract] [Full Text] [Related]

  • 17. [Study on the immunogenicity of HIV-1 gag vaccine].
    Jiang WZ, Jin NY, Li ZJ, Zhang LS.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May 20; 20(3):272-3. PubMed ID: 15193215
    [Abstract] [Full Text] [Related]

  • 18. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.
    Liu J, Wyatt LS, Amara RR, Moss B, Robinson HL.
    Vaccine; 2006 Apr 12; 24(16):3332-9. PubMed ID: 16472543
    [Abstract] [Full Text] [Related]

  • 19. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Gómez CE, Nájera JL, Sánchez R, Jiménez V, Esteban M.
    Vaccine; 2009 May 21; 27(24):3165-74. PubMed ID: 19446187
    [Abstract] [Full Text] [Related]

  • 20. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha.
    Lekutis C, Shiver JW, Liu MA, Letvin NL.
    J Immunol; 1997 May 01; 158(9):4471-7. PubMed ID: 9127013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.